Collaboration Opportunities

Oncotelic is actively seeking collaborations with corporations, academic institutions, and patient groups to advance our programs. We have a history of successful partnerships and welcome new collaboration and licensing opportunities.

Interested parties may contact:
Chulho Park PhD,  Chief Technology Officer
Oncotelic Inc.
29397 Agoura Rd., Suite 107
Agoura Hills, CA 91301
bd@oncotelic.com
(650) 635-7000

Partners

The Christie Hospital NHS Foundation Trust

Through our history of collaborative research, Mateon has supported clinical research projects in the United Kingdom (UK) led by Cancer Research UK (CRUK) along with additional academic partners. Currently, we are supporting the PAZOFOS study (NCT02055690), which is being led by The Christie Hospital NHS Foundation Trust and coordinated by the Manchester Academic Health Science Centre, Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust, and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust). This Phase 1b/2 study is evaluating the combination of CA4P (fosbretabulin) with the tyrosine kinase inhibitor pazopanib (Votrient®) versus pazopanib alone for the treatment of advanced recurrent ovarian cancer. We are providing CA4P for use in this trial.

University of Kentucky, Markey Cancer Center

Continuing in our history of collaborative research, Mateon is providing investigational drug to the Markey Cancer Center for their study Study MCC-2016-08 (NCT03014297). The study is designed as a single center, open label, phase 1 clinical trial for patients with grade 1-3 gastroenteropancreatic neuroendocrine tumors. In the first part of the study, up to 15 patients will be treated with everolimus in combination with two different dosing regimens of CA4P to establish appropriate CA4P dosing levels and evaluate the safety of the drug combination.  The second part of the study is designed to enroll 15 additional patients for assessment of additional safety and efficacy data. Patients enrolled in MCC-2016-088 will be treated with CA4P and everolimus for 12 weeks.